Literature DB >> 11417302

Detection of malignant cells in pleural fluid or ascites by CD44v8-10/CD44v10 competitive RT-PCR.

M J Ahn1, Y H Noh, H J Yoon, S C Yang, J W Sohn, J H Choi, Y Y Lee, I Y Choi, I S Kim, Y S Lee, C K Park.   

Abstract

BACKGROUND: CD44 is a cell surface adhesion molecule which has been implicated in various biologic functions as lymphocyte homing and activation, cellular migration and extracellular matrix adhesion. Over-expression of CD44v8-10 has been found in several cancers and is considered to be associated with tumor progression and metastasis. Recently, a novel molecular method, CD44v8-10/CD44v10 competitive reverse transcription-polymerase chain reaction(RT-PCR) has been developed for detecting cancer cells over-expressing CD44v8-10.
METHODS: We analyzed from benign and malignant pleural effusion and ascites by CD44 competitive RT-PCR and compared to the conventional cytology.
RESULTS: The CD44 competitive RT-PCR analysis showed that all the 24 samples associated with benign disease presented a predominant expression of the CD44v10 transcript (v8-10/v10 ratio: 0.126-0.948), whereas 6 of 7 malignant pleural samples associated with cytology positive cancer expressed the CD44v8-10 transcript (v8-10/v10 ratio > 1.00).
CONCLUSION: These results indicate that CD44 competitive RT-PCR assay is a useful and adjunct to cytological examination in cancer diagnosis, especially in detecting exfoliated cancer cells in pleural effusion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11417302      PMCID: PMC4531696          DOI: 10.3904/kjim.2001.16.1.30

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  21 in total

1.  Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain.

Authors:  D G Jackson; J Buckley; J I Bell
Journal:  J Biol Chem       Date:  1992-03-05       Impact factor: 5.157

2.  CD44 and cancer screening.

Authors:  S B Fox; K C Gatter; D G Jackson; G R Screaton; M V Bell; J I Bell; A L Harris; D Simmons; J Fawcett
Journal:  Lancet       Date:  1993-08-28       Impact factor: 79.321

3.  Expression of CD44 splice variants in colorectal cancer.

Authors:  L S Wong; J E Cantrill; A G Morris; I A Fraser
Journal:  Br J Surg       Date:  1997-03       Impact factor: 6.939

4.  CD44 expression patterns in breast and colon tumors: a PCR-based study of splice variants.

Authors:  C Rodriguez; G Monges; P Rouanet; B Dutrillaux; D Lefrançois; C Theillet
Journal:  Int J Cancer       Date:  1995-10-20       Impact factor: 7.396

Review 5.  Are CD44 variant isoforms involved in human tumour progression?

Authors:  U Günthert; R Stauder; B Mayer; H J Terpe; L Finke; K Friedrichs
Journal:  Cancer Surv       Date:  1995

6.  Expression of CD44R1 adhesion molecule in colon carcinomas and metastases.

Authors:  K K Tanabe; L M Ellis; H Saya
Journal:  Lancet       Date:  1993-03-20       Impact factor: 79.321

7.  T-cell-receptor-independent activation of cytolytic activity of cytotoxic T lymphocytes mediated through CD44 and gp90MEL-14.

Authors:  A Seth; L Gote; M Nagarkatti; P S Nagarkatti
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

8.  Pleural effusion in lung cancer.

Authors:  S A Sahn
Journal:  Clin Chest Med       Date:  1993-03       Impact factor: 2.878

9.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons.

Authors:  G R Screaton; M V Bell; D G Jackson; F B Cornelis; U Gerth; J I Bell
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

10.  CD44H regulates tumor cell migration on hyaluronate-coated substrate.

Authors:  L Thomas; H R Byers; J Vink; I Stamenkovic
Journal:  J Cell Biol       Date:  1992-08       Impact factor: 10.539

View more
  1 in total

1.  Rapid and reliable detection of CD44 variants in gastric carcinoma using a nested reverse transcription-polymerase chain reaction.

Authors:  Yan Wang; Yuhong Liu; Bai Xiao
Journal:  Oncol Lett       Date:  2015-09-02       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.